Special Issue "Cytoreductive Surgery Treatment: Advances and Obstacles"
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 3758
Interests: surgery; clinical trials; oncology
Peritoneal dissemination of intra-abdominal malignancies is generally regarded as an unfavorable prognostic indicator. Historically, therapeutic interventions in cases of peritoneal carcinomatosis (PC) were minimal. However, the introduction of cytoreductive surgery (CRS) allowed the macroscopic removal of the peritoneal metastatic foci, while in parallel, the administration of intraperitoneal hyperthermic chemotherapy (HIPEC) enabled the management of the microscopic residual disease, thus improving the survival and quality of life outcomes. The perioperative safety and oncological efficacy of CRS and HIPEC have been confirmed by multiple trials, in various clinical settings. Despite the wide acceptance of CRS, there is still a considerable discrepancy in terms of operative indications, surgical techniques and treatment protocols.
We are pleased to invite you to the “Cytoreductive Surgery Treatment: Advances and Obstacles” Special Issue of Current Oncology. This Special Issue aims to highlight the recent innovations in both cytoreductive surgery and intraperitoneal chemotherapy, while also addressing all current application issues and future research directions.
In this Special Issue, original research articles and reviews are welcome. Research areas may include, but are not limited to, the following:
- Patient selection and preoperative risk stratification;
- Enhanced recovery after CRS;
- Acceleration of the learning curve;
- Adjunctive techniques in CRS;
- HIPEC and associated alternatives;
- Novel predictive biomarkers;
- Improving oncological efficacy;
- Current and emerging chemotherapeutic agents.
We look forward to receiving your contributions.
Dr. Konstantinos Perivoliotis
Prof. Dr. Konstantinos Tepetes
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.